Why Cushing's Tumors Stop Responding to Temozolomide
New research reveals how corticotroph pituitary tumors develop resistance to temozolomide through clonal selection of high MGMT-expressing cells.
Summary
Temozolomide is one of the few drug options for aggressive pituitary tumors that cause Cushing's disease, but tumors often stop responding after initial treatment. This study examined why. Researchers found that 80% of corticotroph pituitary tumors show highly variable levels of a DNA-repair protein called MGMT, both between tumors and within the same tumor. In lab models, exposing corticotroph tumor cells to temozolomide — even at low, clinically realistic doses — caused cells to become significantly resistant over time. That resistance came with sharply elevated MGMT levels. The likely explanation: cells that naturally had higher MGMT survived the drug and multiplied, eventually dominating the tumor. This clonal selection mechanism offers a new framework for understanding treatment failure and may point toward strategies to overcome or prevent resistance in patients with refractory Cushing's disease.
Detailed Summary
Aggressive pituitary tumors, particularly corticotroph adenomas that drive Cushing's disease, represent a serious unmet medical need. Surgery and radiation often fail to achieve durable control, and systemic medical options are limited. Temozolomide, an oral alkylating chemotherapy agent, has emerged as an important option — but many patients who initially respond eventually experience tumor regrowth that no longer responds to the drug. Understanding why is critical for improving outcomes.
This study, published in the Journal of Clinical Endocrinology and Metabolism, investigated the role of MGMT — a DNA-repair enzyme that directly counteracts temozolomide's mechanism of action — in acquired resistance. Researchers analyzed MGMT expression patterns across 25 human corticotroph tumors using immunohistochemistry and developed in vitro resistance models using AtT20 corticotroph cells exposed to both high and low doses of temozolomide.
The tissue analysis revealed striking heterogeneity: 80% of tumors showed variable MGMT staining both across different tumors and within individual tumors. This intratumoral patchwork of MGMT-expressing and MGMT-low cells has direct implications for treatment response. In the cell models, exposure to temozolomide induced 6.3-fold (high-dose) and 3.4-fold (low-dose) reductions in drug sensitivity. Resistant cells showed markedly elevated MGMT mRNA and protein levels and an 80% increase in the proportion of MGMT-positive cells, without changes in MGMT promoter methylation — suggesting expression upregulation rather than epigenetic reprogramming.
The researchers propose that clonal selection drives resistance: MGMT-high cells that were present from the start survive chemotherapy exposure, proliferate, and come to dominate the tumor population. This would explain why re-treatment with temozolomide typically fails after initial resistance develops.
Clinically, these findings suggest that MGMT heterogeneity may need to be considered when interpreting biopsy results and predicting treatment response. Strategies targeting MGMT — including MGMT inhibitors or combination regimens — may warrant investigation to prevent or overcome acquired resistance in this difficult-to-treat patient population.
Key Findings
- 80% of corticotroph pituitary tumors show high variability in MGMT expression within and between tumors.
- Temozolomide exposure induced up to 6.3-fold decreased drug sensitivity in corticotroph tumor cells.
- Resistant cells had significantly higher MGMT mRNA, protein levels, and more MGMT-positive cells.
- MGMT promoter methylation was unchanged, suggesting resistance arises from clonal selection, not epigenetic change.
- Even low, clinically achievable temozolomide doses were sufficient to induce meaningful acquired resistance.
Methodology
The study analyzed MGMT immunohistochemistry in 25 human corticotroph adenoma samples to assess intertumoral and intratumoral heterogeneity. In vitro TMZ resistance was modeled using AtT20 murine corticotroph cells exposed to high- and low-dose temozolomide, with resistance characterized by growth inhibition assays, cell cycle analysis, and MGMT mRNA/protein quantification.
Study Limitations
This summary is based on the abstract only, as the full text is not open access. The in vitro model uses murine AtT20 cells, which may not fully replicate human tumor biology. The sample size of 25 tumors limits generalizability of the heterogeneity findings.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.